GAD2 and type 1 diabetes mellitus: Twelve recent-onset T1D patients administration of GAD65 Alum as a preventative intervention in stage 1 healthy pediatric patients with antibody positivity (treatment: 13 patients, placebo: 13 patients) yielded promising preliminary results and showed significantly lower levels of T cells (P = .008), T-helper cells (P = .014), and cytotoxic T-cells (P = .023) 26 months posttreatment (Salami et al, 2022).